In clinical samples as well as in CCLE cancer cell lines, the presence of oncogenic mutations and CNVs in various driver genes is associated with variations in AGR2/3 expression, depending both on the cancer gene and the tumour type. This evidence concerns the gene AGR2 and cancer.